Skip to main content
SpringerLink
Log in

Are all-oral direct-acting antivirals cost effective in chronic hepatitis C?

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was supported by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Reference

  • Yuen MF, et al. Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong. Digestive Diseases and Sciences : 8 May 2020. Available from: URL: http://doi.org/10.1007/s10620-020-06281-8

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Are all-oral direct-acting antivirals cost effective in chronic hepatitis C?. PharmacoEcon Outcomes News 853, 5 (2020). https://doi.org/10.1007/s40274-020-6800-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-6800-y

Search

Navigation